Abstract
The hydrolysis of cefamandole nafate was examined in vivo in five dialysis patients and five subjects with normal renal function. The plasma half-life of cefamandole was prolonged in the patients with renal failure compared with normal subjects (18.3 +/- 4.5 [standard deviation] versus 10.35 +/- 1.4 min, P less than 0.01). The pharmacokinetics of cefamandole nafate best fit two-compartment, open-model kinetics. We conclude that patients with severe renal failure are capable of hydrolyzing cefamandole nafate to cefamandole and formate at a rate sufficiently rapid so as not to allow an accumulation of cefamandole nafate. The difference in half-life may be related to urinary excretion of cefamandole nafate in normal individuals.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Gomeni C., Gomeni R. IGPHARM: interactive graphic package for pharmacokinetic analysis. Comput Biomed Res. 1978 Aug;11(4):345–361. doi: 10.1016/0010-4809(78)90017-4. [DOI] [PubMed] [Google Scholar]
- Indelicato J. M., Wilham W. L., Cerimele B. J. Conversion of cefamandole nafate to cefamandole sodium. J Pharm Sci. 1976 Aug;65(8):1175–1178. doi: 10.1002/jps.2600650811. [DOI] [PubMed] [Google Scholar]
- Turner J. R., Preston D. A., Wold J. S. Delineation of the relative antibacterial activity of cefamandole and cefamandole nafate. Antimicrob Agents Chemother. 1977 Jul;12(1):67–72. doi: 10.1128/aac.12.1.67. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wick W. E., Preston D. A. Biological properties of three 3-heterocyclic-thiomethyl cephalosporin antibiotics. Antimicrob Agents Chemother. 1972 Mar;1(3):221–234. doi: 10.1128/aac.1.3.221. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wold J. S., Joost R. R., Black H. R., Griffith R. S. Hydrolysis of cefamandole nafate to cefamandole in vivo. J Infect Dis. 1978 May;137 (Suppl):S17–S24. doi: 10.1093/infdis/137.supplement.s17. [DOI] [PubMed] [Google Scholar]